Corporate Banner
Satellite Banner
Genotyping & Gene Expression
Scientific Community
Become a Member | Sign in
Home>News>This Article

Ariana Appoints Dr Mariana Kuras as Chief Technology Officer

Published: Wednesday, August 22, 2012
Last Updated: Wednesday, August 22, 2012
Bookmark and Share
CTO appointment reinforces senior management expertise in biomarker industry.

Ariana Pharma has announced that it has appointed Dr. Mariana Kuras as its chief technology officer.

Mariana brings to Ariana eight years of experience at Biosystems International.

Whilst director of research, she was responsible for the development and validation of biomarker platform technologies in multi-million euro projects.

These technologies included the application of antibodies to various diseases, including oncology and neurodegenerative diseases.

Mariana and her team contributed towards the development of thousands of antibodies used on microarrays and to the patenting and publication of biomarker signatures and paving their route to market.

As a genomics and bioinformatics scientist at Pfizer Global Research and Development, Fresnes, France, Mariana has also been responsible for genomic studies.

She has also been an independent scientific expert for the sixth and seventh framework of the European Commission and vice-chair for the life sciences panel for sixth PCRD of the research and training networks for the European Commission.

She was awarded a PhD in biophysics and computational biology from the University of Illinois at Urbana-Champaign, USA.

“Mariana brings an exceptional level of both industrial and scientific experience to Ariana,” said Dr. Mohammad Afshar, president and CEO of Ariana Pharma.

Dr. Afshar continued, “Demand for our biomarker activity has continued to increase dramatically as a result of the drive in life science industries to personalized medicine. Mariana’s unique hands-on experience of both computational and experimental aspects of biomarker development will be a key asset to Ariana. She will help Ariana continue to meet our client’s growing needs.”

“Ariana has become one of the most promising international players in diagnostic and personalized medicine,” said Dr. Mariana Kuras.

Dr. Kuras continued, “By providing a validated solution to the challenge of combining heterogenous data from multiple sources with patient characteristics, Ariana will continue to grow as industry demand continues to increase and I am looking forward to adding my experience to the Ariana effort.”

KEM® - or Knowledge Extraction and Management - is an association rules-based (non-statistical) analytical technology that finds patient responder sub-populations and biomarker signatures that statistical methods are unable to detect.

KEM optimizes clinical trial inclusion/exclusion criteria thereby lowering the number of patients needed to reach clinical endpoints and saving sponsors both time and money.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,600+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Ariana® Expands Operations to USA
Company also appoints James M. Shanahan VP business development of subsidiary “Ariana Data Intelligence, Inc.”
Monday, June 04, 2012
Scientific News
Chromosomal Chaos
Penn study forms basis for future precision medicine approaches for Sezary syndrome
Shaking Up the Foundations of Epigenetics
Researchers at the Centre for Genomic Regulation (CRG) and the University of Barcelona (UB) published a study that challenges some of the current beliefs about epigenetics.
Cell's Waste Disposal System Regulates Body Clock Proteins
New way to identify interacting proteins could identify potential drug targets.
Compound Doubles Up On Cancer Detection
Researchers have found that tagging a pair of markers found almost exclusively on a common brain cancer yields a cancer signal that is both more obvious and more specific to cancer.
Lung Repair and Regeneration Gene Discovered
New role for hedgehog gene offers better understanding of lung disease.
Mixed Up Cell Transportation Key Piece of ALS and Dementia Puzzle
Researchers from the University of Toronto are one step closer to solving this incredibly complex puzzle, offering hope for treatment.
Five New Genetic Variants Linked to Brain Cancer Identified
The biggest ever study of DNA from people with glioma – the most common form of brain cancer – has discovered five new genetic variants associated with the disease.
Predictive Model for Breast Cancer Progression
Biomedical engineers have demonstrated a proof-of-principle technique that could give women and their oncologists more personalized information to help them choose options for treating breast cancer.
New Hope for Personalized Treatment of Eczema
Pharmaceutical researchers at Oregon State University have developed a new approach to treat eczema and other inflammatory skin disorders that would use individual tests and advanced science to create personalized treatments based on each person's lipid deficiencies.
Gene Expression: A Snapshot of Stem Cell Development
New genes found that regulate development of stem cells.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,600+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos